About Athenese-Dx
Athenese-Dx is a company based in Chennai (India) founded in 2012. It operates as a B2B and D2C. The company has 289 employees. Athenese-Dx offers products and services including Rapid Tests, ELISA Kits, Fluorescence Immuno Assay, Clinical Chemistry, and Molecular PCR Instruments. Athenese-Dx operates in a competitive market with competitors including Inflammatix, MeMed, GenMark Diagnostics, Sunbird Bio and T2 Biosystems, among others.
- Headquarter Chennai, India
- Employees 289
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website athenesedx.com
- Social LinkedIn X Facebook Instagram YouTube
- Legal Name Athenese-Dx Private Limited
- Date of Incorporation 24 Feb, 2012
- Jurisdiction Chennai, Tamil Nadu, India
- Annual Revenue₹73.45 Cr
FY 2024 · +1% YoY
- Net Profit₹4.26 Cr
FY 2024 · 6% margin
- EBITDA₹6.74 Cr
FY 2024 · 9% margin
- Employee Count289
Associated legal entities of Athenese-Dx
Athenese-Dx operates through Athenese-Dx Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Athenese-Dx Private Limited CIN U85100TN2012PTC084632 | Active | 24 Feb 2012 | Chennai, Tamil Nadu | ₹73.4 Cr | 289 | 3 | View details |
Products & Services of Athenese-Dx
Athenese-Dx offers a comprehensive portfolio of products and services, including Rapid Tests, ELISA Kits, Fluorescence Immuno Assay, Clinical Chemistry, and Molecular PCR Instruments.
Quick tests for accurate disease diagnosis in various categories
Kits for reliable enzyme-linked immunosorbent assays
Cost-effective assays for immediate diagnostic results
Products for profiling diabetic, lipid, and cardiac conditions
Instruments for molecular diagnostics and PCR analysis
Apps and channels of Athenese-Dx
its YouTube channel Athenese-Dx has 691 subscribers and 21 videos.
Videos from Athenese-Dx
The most watched videos on Athenese-Dx's YouTube channel, Athenese-Dx (691 subscribers). Click a video to play it here.
More on Athenese-Dx.
Board of directors of Athenese-Dx Private Limited (Athenese-Dx)
Athenese-Dx Private Limited is the primary company behind Athenese-Dx. The board of Athenese-Dx Private Limited currently have 3 directors; the longest-serving is Arunkumar Chakravarthy, appointed in 2017. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Arunkumar Chakravarthy DIN 07692835 | Whole-time director | 06 Jan 2017 | 9 yrs 9 mo | Athenese-Dx Private Limited |
| Catherine Yaping Chen DIN 07375426 | Director | 30 Dec 2020 | 5 yrs 9 mo | Athenese-Dx Private Limited |
| Srikrishnan DIN 11379544 | Additional Director | 14 Nov 2025 | 10 mo | Athenese-Dx Private Limited |
Financials of Athenese-Dx
Figures of Athenese-Dx Private Limited, the primary company behind Athenese-Dx, for FY 2024. Revenue was ₹73.45 Cr (+1% year on year). Net profit was ₹4.26 Cr (6% margin). EBITDA was ₹6.74 Cr (9% margin). Revenue has grown at a compounded annual rate of +12% over three years and +15% over five years.
- ₹73.45 CrRevenue · FY 2024 · +1% YoY
- ₹4.26 CrNet profit · 6% margin
- ₹6.74 CrEBITDA · 9% margin
- ₹0.70 CrPaid-up capital
- 289Employees (provident fund records)
- +12%Revenue CAGR, 3 years
- +15%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Athenese-Dx Private Limited are on its company page.
Detailed financial statements for Athenese-Dx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Athenese-Dx
Athenese-Dx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, MeMed, GenMark Diagnostics, Sunbird Bio and T2 Biosystems, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.5M | 54 | Provider of diagnostic solutions for systemic infections | |
| me-med.com | 2009 | Tirat Carmel, Israel | $163.0M | – | Provider of machine learning based diagnostic solutions for infectious diseases | |
| genmarkdx.com | 1993 | San Diego, United States | $8.6M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| sunbirdbio.com | 2020 | Singapore | $14.0M | – | Diagnostic technologies for infectious, cancer, and neurological diseases are developed. | |
| t2biosystems.com | 2006 | Lexington, United States | $454.3M | 166 | Miniaturized MRI platforms for clinical diagnostics are developed. | |
| kariusdx.com | 2014 | Redwood, United States | $315.0M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| molbiodiagnostics.com | 2000 | Salcete, India | $124.0M | 714 | Point-of-care molecular platforms for infectious disease detection are developed. | |
| visbymedical.com | 2010 | San Jose, United States | $386.3M | 251 | Portable PCR diagnostics for infectious diseases are developed. | |
| kryptosbio.com | 2017 | Hayward, United States | $12.7M | – | Point-of-care molecular diagnostics are enabled by Ultrafast Photonic PCR technology. | |
| curetis.com | 2007 | Holzgerlingen, Germany | $127.1M | 55 | Molecular diagnostics platform is provided for infectious disease detection. |
Detailed competitors of Athenese-Dx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Athenese-Dx
Complete news archive for Athenese-Dx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Athenese-Dx
10 companies that operate in the same segment as Athenese-Dx (Clinical Genomics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Panomic profiling technologies are developed for cancer precision medicine. | 1996 | Irving, Texas, United States | USD 1.23 B | – | 1,339 | |
Genomics-based diagnostic tests for cancer are provided. | 2010 | Cambridge, Massachusetts, United States | USD 96.5 M | – | – | |
Digital molecular biology analytics are developed for disease management. | 2012 | Carlsbad, California, United States | USD 95.02 M | – | 46 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Genomic database for clinical research is provided. | 2015 | San Francisco, California, United States | USD 435 M | – | – | |
Genomic sequencing and diagnosis software is provided for healthcare. | 2011 | Menlo Park, California, United States | USD 87.3 M | USD 69.65 M | 229 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Athenese-Dx
Athenese-Dx was founded in 2012.
Athenese-Dx is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.
Athenese-Dx has 289 employees.
The primary company behind Athenese-Dx, Athenese-Dx Private Limited, reported revenue of ₹73.45 Cr for FY 2024, up 1% year on year.
Athenese-Dx focuses on researching, developing, manufacturing, and marketing in vitro diagnostic tests and instruments. The company offers products like rapid tests, ELISA kits, clinical chemistry, fluorescence immunoassays, and molecular diagnostics. Based in Chennai, India, with a branch in New Delhi, it serves healthcare providers and laboratories globally. Their RD is recognized by the Department of Scientific and Industrial Research, emphasizing quality and innovation in diagnostics.
Athenese-Dx's top competitors include Visby Medical, Inflammatix and MeMed.
Athenese-Dx offers Rapid Tests, ELISA Kits, Fluorescence Immuno Assay, Clinical Chemistry, and Molecular PCR Instruments.
Athenese-Dx operates through Athenese-Dx Private Limited.
The legal entities of Athenese-Dx currently have 3 directors, including Arunkumar Chakravarthy, Catherine Yaping Chen, Srikrishnan.